Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?
نویسندگان
چکیده
منابع مشابه
Formulation and Evaluation of Nanocrystals of a Lipid Lowering Agent
Atorvastatin calcium, the lipid lowering agent, is taken as a model drug characterized by poor water solubility and bioavailability. In this study an attempt was made for preparation of nanocrystals using high pressure homogenization. A number of stabilizers were included as well as polymers at different concentrations, and the formulations were homogenized for ten cycles at a pressure of 1000 ...
متن کاملFormulation and Evaluation of Nanocrystals of a Lipid Lowering Agent
Atorvastatin calcium, the lipid lowering agent, is taken as a model drug characterized by poor water solubility and bioavailability. In this study an attempt was made for preparation of nanocrystals using high pressure homogenization. A number of stabilizers were included as well as polymers at different concentrations, and the formulations were homogenized for ten cycles at a pressure of 1000 ...
متن کاملDoes it Matter Whether the EPA Targets Volumetric or Fractional RFS Standards?
In a farmdoc daily article last week (June 3, 2015), we analyzed whether the ethanol mandates recently proposed by the EPA for 2015 and 2016 were high enough to provide a “push” for biofuels use beyond the E10 blend wall. The analysis confirmed that the proposed mandates do indeed imply pressure towards higher ethanol blends or non-ethanol biofuel, but this depends on assumptions about growth i...
متن کاملWhen is a lipid kinase not a lipid kinase? When it is a protein kinase
About 10 years ago there was a heated debate over whether v-Src and several other retrovirally encoded protein-tyrosine kinases had lipid kinase activity in addition to protein kinase activity. Ultimately, the analysis of the unusual lipid kinase activity associated with v-Src led to the discovery of a novel type of phosphatidylinositol (PI) kinase, the PI 3-kinases. This in turn led to the cha...
متن کاملCilostazol--a forgotten antiplatelet agent, but does it even matter?
Cilostazol is a phosphodiesterase III inhibitor that has antiplatelet effects due to subsequent increases in cyclic adenosine monophosphate within platelets (1). This agent also provides vasodilation, improves endothelial function, inhibits vascular smooth muscle cell growth, inhibits neointimal hyperplasia, and seems to reduce the risk of restenosis and major adverse cardiac events (MACE) afte...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Atherosclerosis Reports
سال: 2007
ISSN: 1523-3804,1534-6242
DOI: 10.1007/s11883-007-0049-9